Glofitamab ELISA Kit (DY257048)

データシート製品共有情報コピー

概要
イメージ
参考文献
データシート
SDS

カタログ番号	DY257048
説明	Glofitamab ELISA Kit (DY257048) — Quantitative sandwich ELISA for Glofitamab. Sample: Plasma, Serum. Range: 0.31-5 μg/mL. Sensitivity: 0.156 μg/ml. Highlights ●Sandwich Format — High specificity, reliable quantification. ●High Sensitivity — Optimized for low-abundance target detection. ●Ready-to-Use — Complete kit with pre-coated plates included.
サンプルタイプ	Plasma, Serum
感度	0.29 ng/ml
レンジ	1.56-100 ng/ml
アクセッション番号	P11836 & P07766
アプリケーション	ELISA
検出方法	Colorimetric
アッセイタイプ	Quantitative
回収率	80-120%
発送	2-8 ℃
安定性と保存	The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
仕様	Glofitamab
別名	CD20-TCB (2:1), RG-6026, 2229047-91-8
背景	Glofitamab (RG6026) is a novel T-cell-engaging, bispecific antibody that binds bivalently to CD20 on B cells, and monovalently to CD3 on T cells. In study NP30179 (NCT03075696), an ongoing Phase I/II dose-escalation and expansion study, glofitamab fixed-dosing (0.6-25mg) with obinutuzumab pre-treatment (Gpt) achieved high, durable CRs with manageable safety in pts with heavily pre-treated R/R NHL (Dickinson et al. EHA 2020). Step-up dosing (SUD) of glofitamab, in addition to Gpt, allowed dose-escalation up to the highest planned dose of 30mg to maximize efficacy, while mitigating cytokine release syndrome (CRS; [Hutchings et al. J Clin Oncol 2021]). We present updated duration of response (DoR) data from the glofitamab monotherapy fixed-dosing and SUD cohorts of study NP30179 in pts with R/R NHL.
注意事項	For Research Use Only.